Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 8/2019

01-08-2019 | Original Article

Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study

Authors: Jee Soo Park, Yong Seung Lee, Cho Nyeong Lee, Sung Hoon Kim, Sang Woon Kim, Sang Won Han

Published in: World Journal of Urology | Issue 8/2019

Login to get access

Abstract

Purpose

Antimuscarinics are the first pharmacological treatment option for neurogenic bladder in children with spina bifida but side effects limit their use. Mirabegron, a new β-3 adrenoceptor agonist with a distinct mechanism of action, is a potential agent for the treatment of neurogenic bladder; however, it has yet to be studied in the pediatric population. This study evaluated the efficacy and safety of mirabegron for treating neurogenic bladder in children with spina bifida.

Materials and methods

Clinical and urodynamic parameters were retrospectively studied in 66 children (under 18 years of age) with spina bifida who were treated for neurogenic bladder with mirabegron at Severance Children’s Hospital between July 2015 and December 2017. Pediatric patients received 50 mg mirabegron daily for at least 6 weeks either in addition to or instead of antimuscarinic therapy. Urodynamic parameters, including compliance, involuntary detrusor contraction, and maximum cystometric capacity, as well as patient-reported efficacy and adverse events, were measured.

Results

In both groups post-treatment, incontinence significantly improved. In addition, maximum cystometric capacity and compliance significantly increased post-treatment. Six patients reported side effects (constipation, 4.5%; headache, 3.0%; and hypertension, 1.5%) and three patients discontinued treatment.

Conclusion

We evaluated the efficacy and safety of mirabegron for treating neurogenic bladder in pediatric patients with spina bifida. All clinical and urodynamic parameters improved with treatment. Prospective, placebo-controlled studies are necessary to confirm these findings.
Literature
1.
Liu JS, Dong C, Casey JT et al (2015) Quality of life related to urinary continence in adult spina bifida patients. Cent Eur J Urol 68:61–67CrossRef
2.
de Jong TP, Chrzan R, Klijn AJ et al (2008) Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol 23:889–896CrossRef
3.
Parekh AD, Trusler LA, Pietsch JB et al (2006) Prospective, longitudinal evaluation of health related quality of life in the pediatric spina bifida population undergoing reconstructive urological surgery. J Urol 176:1878–1882CrossRef
4.
Hopps CV, Kropp KA (2003) Preservation of renal function in children with myelomeningocele managed with basic newborn evaluation and close followup. J Urol 169:305–308CrossRef
5.
Sturm RM, Cheng EY (2016) The management of the pediatric neurogenic bladder. Curr Bladder Dysfunct Rep 11:225–233CrossRef
6.
Takasu T, Ukai M, Sato S et al (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647CrossRef
7.
Wollner J, Pannek J (2016) Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (Mirabegron) in patients with spinal cord injury. Spinal Cord 54:78–82CrossRef
8.
Wada N, Okazaki S, Kobayashi S et al (2015) Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation. Hinyokika Kiyo 61:7–11PubMed
9.
Blais AS, Nadeau G, Moore K et al (2016) Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol 70:9–13CrossRef
10.
Kim SW, Choi JH, Lee YS et al (2014) Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. Urology 84:1480–1484CrossRef
11.
Choi EK, Hong CH, Kim MJ et al (2013) Effects of intravesical electrical stimulation therapy on urodynamic patterns for children with spina bifida: a 10-year experience. J Pediatr Urol 9:798–803CrossRef
12.
Neveus T, Von Gontard A, Hoebeke P et al (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol 176:314–324CrossRef
13.
Groen J, Pannek J, Castro Diaz D et al (2016) Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol 69:324–333CrossRef
14.
Kessler TM, Bachmann LM, Minder C et al (2011) Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 6:e16718CrossRef
15.
Yamaguchi O, Chapple CR (2007) Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 26:752–756CrossRef
16.
Andersson KE (2009) Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol 1:71–83CrossRef
17.
Leon LA, Hoffman BE, Gardner SD et al (2008) Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 326:178–185CrossRef
18.
Tyagi P, Tyagi V (2010) Mirabegron, a β3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 13:713–722PubMed
19.
Khullar V, Amarenco G, Angulo JC et al (2013) Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 63:283–295CrossRef
20.
Nitti VW, Auerbach S, Martin N et al (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189:1388–1395CrossRef
21.
Chapple CR, Kaplan SA, Mitcheson D et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296–305CrossRef
22.
Nitti VW, Khullar V, van Kerrebroeck P et al (2013) Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, doubleblind, placebo-controlled, phase III studies. Int J Clin Pract 67:619–632CrossRef
23.
Chapple CR, Cardozo L, Nitti VW et al (2013) Mirabegron in overactive bladder: a review of efficacy, safety and tolerability. Neurourol Urodyn 33:17–30CrossRef
24.
Andersson KE (2013) Beta3-receptor agonists for overactive bladder-new frontier or more of the same? Curr Urol Rep 14:435–441CrossRef
25.
Apostolidis A (2017) Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations? BJU Int 120:459–460CrossRef
26.
Nitti VW, Chapple CR, Walters C et al (2014) Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomized phase III trial. Int J Clin Pract 68:972–985CrossRef
Metadata
Title
Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study
Authors
Jee Soo Park
Yong Seung Lee
Cho Nyeong Lee
Sung Hoon Kim
Sang Woon Kim
Sang Won Han
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 8/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2576-0

Other articles of this Issue 8/2019

World Journal of Urology 8/2019 Go to the issue

Original Article

Minimally invasive management of ureteral strictures: a 5-year retrospective study

Editorial

Recurrence in prostate cancer: salvage diagnostic and therapeutic strategies

Original Article

Outcomes of magnetic resonance imaging fusion-targeted biopsy of prostate imaging reporting and data system 3 lesions

Topic Paper

The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer

Topic Paper

Metastasectomy for visceral and skeletal oligorecurrent prostate cancer

Invited Review

Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis